KIMMTRAK (tebentafusp)
HLA-A*02:01-positive metastatic uveal melanoma
ApprovedCommercial
Key Facts
Indication
HLA-A*02:01-positive metastatic uveal melanoma
Phase
Approved
Status
Commercial
Company
About Immunocore
Immunocore's mission is to pioneer and deliver transformative immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases. Its defining achievement is the 2022 FDA approval of KIMMTRAK (tebentafusp), the world's first TCR therapy, which validates its core ImmTAX platform technology. The company's strategy is to leverage this validated, modular platform to build a broad pipeline of bispecific TCR therapies, controlling value from discovery through commercialization. With a strong leadership team and a first-mover advantage in TCR therapeutics, Immunocore is positioned as a leader in next-generation immunotherapy.
View full company profile